Skip to content

A Virome study of diabetic foot wound infections

A Virome study of diabetic foot wound infections

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044669
Enrollment
Unknown
Registered
2021-03-25
Start date
2021-03-17
Completion date
Unknown
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot

Interventions

diabetic foot infections:Nil

Sponsors

Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged >=18 and <= 70 years, male or female; (2) Diagnosed with type 2 diabetes (diabetes inclusion criteria were based on the diabetes diagnostic criteria proposed by WHO Diabetes Expert Committee in 2005); (3) Conformed to the diagnosis of diabetic foot and Wagner grade (grade 2-3);Attachment: Wagner classification: 0 level (complete skin), I level (superficial ulcer), II level (deep ulcer consolidated soft tissue infection), III level (deep ulcer And abscess or osteomyelitis, IV level (part of the foot gangrene), V level (full foot gangrene bad); (4) No serious complications or other serious diseases (such as severe liver and kidney insufficiency, sepsis, etc.), and no absolute surgical contraindication; (5) Patients were informed and voluntarily participated in this study.

Exclusion criteria

Exclusion criteria: (1) Uncontrollable hyperglycemia (such as HbA1c > 12.0%), diabetic ketoacidosis, non-ketoosmotic coma; (2) Complicated with malignant tumor; (3) Pregnant or lactating women; (4) Other diseases or mental illnesses that researchers think may limit efficacy evaluation or patient follow-up and are difficult to cooperate with the successful completion of the study; (5) Patients with serious uncontrolled diseases or systemic acute infection or with other serious organ diseases such as liver, kidney, heart, lung and brain diseases; (6) Those considered inappropriate by researchers; (7) Those who had participated in other clinical trials in the three months before the experiment.

Design outcomes

Primary

MeasureTime frame
skin virome;

Secondary

MeasureTime frame
scarring;

Countries

China

Contacts

Public ContactGuangtao Huang

Affiliated Hospital of Zunyi Medical University

haitao0314@qq.com+86 18085287828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026